Neurotoxin Mechanisms and Processes Relevant to Parkinson's Disease: An Update

被引:51
|
作者
Segura-Aguilar, Juan [1 ]
Kostrzewa, Richard M. [2 ]
机构
[1] Univ Chile, Fac Med, Mol & Clin Pharmacol, ICBM, Santiago 7, Chile
[2] E Tennessee State Univ, James H Quillen Coll Med, Dept Biomed Sci, Johnson City, TN 37614 USA
关键词
Parkinson's disease; 6-Hydroxydopamine; MPP+; MPTP; Ortho-quinones; Reactive oxygen species; Rotenone; NEURONAL CELL-DEATH; MPTP MOUSE MODEL; PROTECTS DOPAMINERGIC-NEURONS; ENDOPLASMIC-RETICULUM STRESS; NF-KAPPA-B; NEUROBLASTOMA SH-SY5Y CELLS; MITOCHONDRIAL COMPLEX-I; MPP+-INDUCED APOPTOSIS; PPAR-GAMMA AGONIST; 6-HYDROXYDOPAMINE-INDUCED OXIDATIVE STRESS;
D O I
10.1007/s12640-015-9519-y
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The molecular mechanism responsible for degenerative process in the nigrostriatal dopaminergic system in Parkinson's disease (PD) remains unknown. One major advance in this field has been the discovery of several genes associated to familial PD, including alpha synuclein, parkin, LRRK2, etc., thereby providing important insight toward basic research approaches. There is an consensus in neurodegenerative research that mitochon dria dysfunction, protein degradation dysfunction, aggregation of alpha synuclein to neurotoxic oligomers, oxidative and endoplasmic reticulum stress, and neuroinflammation are involved in degeneration of the neuromelanin-containing dopaminergic neurons that are lost in the disease. An update of the mechanisms relating to neurotoxins that are used to produce preclinical models of ParkinsonA ' s disease is presented. 6-Hydroxydopamine, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, and rotenone have been the most wisely used neurotoxins to delve into mechanisms involved in the loss of dopaminergic neurons containing neuromelanin. Neurotoxins generated from dopamine oxidation during neuromelanin formation are likewise reviewed, as this pathway replicates neurotoxin-induced cellular oxidative stress, inactivation of key proteins related to mitochondria and protein degradation dysfunction, and formation of neurotoxic aggregates of alpha synuclein. This survey of neurotoxin modeling-highlighting newer technologies and implicating a variety of processes and pathways related to mechanisms attending PD-is focused on research studies from 2012 to 2014.
引用
收藏
页码:328 / 354
页数:27
相关论文
共 50 条
  • [31] Parkinson's Disease and Headache: Is there a Relevant Relationship?
    Suzuki, Keisuke
    Fujita, Hiroaki
    Hirata, Koichi
    HEADACHE, 2020, 60 (07): : 1440 - 1441
  • [32] Rare but relevant: Methamphetamine and Parkinson's disease
    Lappin, Julia M.
    ADDICTION, 2024,
  • [33] No relevant midbrain atrophy in Parkinson's disease
    Makinen, E.
    Joutsa, J.
    Isotalo, J.
    Kaasinen, V.
    ACTA NEUROLOGICA SCANDINAVICA, 2016, 134 (05): : 378 - 381
  • [34] Genes relevant for sporadic Parkinson's disease and Alzheimer's disease
    Edna, Gruenblatt
    Peter, Riederer
    JOURNAL OF NEURAL TRANSMISSION, 2008, 115 (10) : 1467 - 1468
  • [35] Drug therapy for Parkinson's disease: An update
    Omar ME Abdel-Salam
    World Journal of Pharmacology, 2015, 4 (01) : 117 - 143
  • [36] Probiotics and the Treatment of Parkinson's Disease: An Update
    Hamed Mirzaei
    Saman Sedighi
    Ebrahim Kouchaki
    Erfaneh Barati
    Ehsan Dadgostar
    Michael Aschner
    Omid Reza Tamtaji
    Cellular and Molecular Neurobiology, 2022, 42 : 2449 - 2457
  • [37] Drugs in development for Parkinson's disease: An update
    Johnston, TH
    Brotchie, JM
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2006, 7 (01) : 25 - 32
  • [38] Update on Molecular Imaging in Parkinson’s Disease
    Zhen-Yang Liu
    Feng-Tao Liu
    Chuan-Tao Zuo
    James B. Koprich
    Jian Wang
    Neuroscience Bulletin, 2018, 34 : 330 - 340
  • [39] Dopaminergic Therapy in Parkinson's Disease: An Update
    Cristobal, Gurutz Linazasoro
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 2008, 30 : 5 - 6
  • [40] Treatment of idiopathic Parkinson's disease: an update
    Kang, Suk Yun
    Sohn, Young Ho
    Kim, Jin-Soo
    NEUROLOGY PSYCHIATRY AND BRAIN RESEARCH, 2005, 12 (03) : 111 - 120